{
    "clinical_study": {
        "@rank": "31629", 
        "arm_group": {
            "arm_group_label": "Ozurdex", 
            "arm_group_type": "Other", 
            "description": "Intra-operative Ozurdex (biodegradable 0.7mg dexamethasone implant) post-vitrectomy for epiretinal membrane"
        }, 
        "brief_summary": {
            "textblock": "To determine if an intravitreal sustained release dexamethasone implant (Ozurdex\u00ae) injected\n      at the conclusion of surgery in patients undergoing vitrectomy and membrane peeling for\n      idiopathic epiretinal membranes is safe and effective to decrease the macular edema, as\n      demonstrated by a gain in vision and decreased in retinal thickness and volume."
        }, 
        "brief_title": "A Pilot Study of the Effectiveness of Intra-operative Ozurdex\u00ae in Vitrectomy Surgery for Epiretinal Membranes", 
        "completion_date": {
            "#text": "November 2013", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Epiretinal Membrane", 
            "Macular Edema"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Edema", 
                "Macular Edema", 
                "Epiretinal Membrane"
            ]
        }, 
        "detailed_description": {
            "textblock": "We believe that the use of intravitreal corticosteroids post-operatively has the capacity to\n      mitigate much of the residual swelling and retinal thickening that is seen after vitrectomy\n      for epiretinal membranes. The unique pharmacokinetics of the sustained released\n      dexamethasone implant (Ozurdex\u00ae) makes it an ideal delivery system to use post-vitrectomy\n      for epiretinal membrane surgery.  Its duration of action and its drug delivery\n      characteristics over 6 months approximately match the post-operative time course of healing\n      and remodeling in an edematous retina.\n\n      This is a prospective, multicentre, pilot study evaluating the efficacy of an intravitreal\n      sustained release dexamethasone implant (Ozurdex\u00ae) injected at the conclusion of surgery in\n      15 patients undergoing vitrectomy and membrane peeling for idiopathic epiretinal membranes."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients undergoing vitrectomy surgery for a visually significant (\u2264 20/50)\n             idiopathic epiretinal membrane.\n\n          -  Central retinal thickness \u2265 250 \u03bcm.\n\n          -  Age more than 18 years old.\n\n          -  Decision makers able to give informed consent.\n\n          -  Females of child bearing potential must agree to use acceptable means of birth\n             control for the duration of the study.\n\n        Exclusion Criteria:\n\n          -  Secondary epiretinal membranes (ex: secondary to a retinal vein occlusion, etc.).\n\n          -  Any other macular pathology that could affect anatomic or functional results.\n\n          -  History of uveitis requiring intravitreal triamcinolone injection.\n\n          -  History of steroid-responsive glaucoma.\n\n          -  History of moderate or advanced glaucoma (cup to disc ratio \u2265 0.7).\n\n          -  IOP > 23 mm Hg if untreated, or > 21 mm Hg if treated with medication.\n\n          -  Pregnant or breast-feeding woman.\n\n          -  Unable to attend the scheduled follow-up appointments.\n\n          -  Patients with known hypersensitivity to any components of Ozurdex\u00ae or to other\n             corticosteroids.\n\n          -  Patients with active or suspected ocular or periocular infections including most\n             viral diseases of the cornea and conjunctiva, including active epithelial herpes\n             simplex keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial\n             infections, and fungal diseases."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "15", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 3, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01701518", 
            "org_study_id": "OZ123", 
            "secondary_id": "OZ123"
        }, 
        "intervention": {
            "arm_group_label": "Ozurdex", 
            "description": "biodegradable 0.7mg dexamethasone implant", 
            "intervention_name": "Ozurdex", 
            "intervention_type": "Drug", 
            "other_name": "0.7mg dexamethasone implant"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Dexamethasone acetate", 
                "Dexamethasone", 
                "Dexamethasone 21-phosphate", 
                "BB 1101"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Ozurdex", 
            "Dexamethasone", 
            "Epiretinal membrane", 
            "Macular edema"
        ], 
        "lastchanged_date": "October 3, 2012", 
        "location": [
            {
                "contact": {
                    "email": "charlene.muller@sunnybrook.ca", 
                    "last_name": "Charlene Muller", 
                    "phone": "416-480-5091"
                }, 
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "M4N 3M5"
                    }, 
                    "name": "Sunnybrook Health Sciences Centre"
                }, 
                "investigator": {
                    "last_name": "Peter J Kertes, MD,CM,FRCSC", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "rajeev.muni@utoronto.ca", 
                    "last_name": "Rajeev Muni, MD, FRCSC", 
                    "phone": "(416) 867-7422"
                }, 
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "M5C 2T2"
                    }, 
                    "name": "St. Michael's Hospital"
                }, 
                "investigator": {
                    "last_name": "Rajeev Muni, MD,FRCSC", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Prospective Multicentre Pilot Study of the Effectiveness of an Intra-operative Intravitreal Sustained Release Dexamethasone Implant (Ozurdex\u00ae) in Vitrectomy Surgery for Epiretinal Membranes", 
        "overall_contact": {
            "email": "charlene.muller@sunnybrook.ca", 
            "last_name": "Charlene Muller", 
            "phone": "416-480-5091"
        }, 
        "overall_official": {
            "affiliation": "Sunnybrook Health Sciences Centre", 
            "last_name": "Peter J Kertes, MD,CM,FRCSC", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Canada: Health Canada", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Best corrected visual acuity measured before surgery and 3 months after surgery using an early treatment diabetic retinopathy study (ETDRS) chart.", 
            "measure": "Best corrected visual acuity", 
            "safety_issue": "No", 
            "time_frame": "3 Months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01701518"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Best corrected visual acuity measured at 1,4 and 6 months after surgery using an early treatment diabetic retinopathy study (ETDRS) chart.", 
                "measure": "Best corrected visual acuity at 1,4 and 6 months", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Measure the change in retinal thickness and volume from baseline and at 1, 3, 4, 6 months using optical coherence tomography (OCT).", 
                "measure": "Retinal thickness and volume", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Change of IOP from baseline will be monitored.", 
                "measure": "Intraocular pressure (IOP)", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "description": "For phakic patients, cataract progression from baseline to the 6 months visit will also be monitored.", 
                "measure": "Cataract progression (if applicable)", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }
        ], 
        "source": "Sunnybrook Health Sciences Centre", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "St. Michael's Hospital, Toronto", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Allergan", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "Sunnybrook Health Sciences Centre", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2012"
    }
}